The American Diabetes Association echoes this guidance, specifically advising patients to check expiration dates on insulin and GLP-1 medications like semaglutide before each use
Before the company applied to the FDA for the drug to be approved for obesity, Knudsen and her colleagues 'developed a new methodology to show how [GLP-1] drugs exert their effect on the brain by working on the circumventricular organs and communicating further into the hypothalamus, among other effects.' This was designed to illustrate how GLP-1 worked in 'well- defined neurons in the hypothalamus, in the hindbrain, and in the reward centers.' Their rationale for developing the method was because 'It was very important to show that these medicines work on defined brain circuits and not ones that may be related to psychiatric or cardiovascular side effects, for example' (Nair
And because GLP-1 drugs measurably reshape the gut microbiome, generally increasing beneficial genera like Akkermansia and Lactobacillus while sometimes reducing overall diversity [11] , supporting microbial balance during treatment is a reasonable strategy for anyone prone to gut dysbiosis
This claim requires Phase 3 confirmation with body composition data
[00:11:03] Emily Field: And at first, that can feel incredibly exciting